Eli Lilly is treating nearly 10% of US obesity population with GLP-1s: CFO
Yahoo Finance Video and Julie Hyman
Wed, August 5, 2026 at 8:32 PM GMT+5:30
- NOVO-B.CO
-4.32% - CVS
-6.25%
After the company reported second quarter earnings and raised its full-year sales guidance, Eli Lilly (LLY) CFO Lucas Montarce outlines the expansion opportunities that the pharmaceutical giant is seeing in its GLP-1 category, specifically the introduction of oral weight-loss drugs to the market
00:00Speaker A
It’s great to see again the momentum that we continue to have. This is not new by the way. 48% growth in the second quarter, but it has been 13 quarters that we have been growing at this pace. And again, you mentioned the race of the guide for the rest of the year, so we continue to see this momentum actually materializing for the rest of the year and the years ahead of us
00:26Speaker A
You talk about Monjaro, of course, almost 10 billion dollars in revenue just for the quarter. This is not only the US but also all US that we see very, very strong growth. And we are actually still in early innings. when you think about the patients that we can serve, in the US we are actually roughly addressing 10% of the patient population in obesity. outside the US, we are talking about 900 million patients that we can serve and we have only served only 2% so far. So big opportunity to continue to drive growth.
01:08Speaker B
When you talk about it being very early, let’s talk about Fundao too. This is of course your oral obesity drug. Revenue for that was $98 million. so still again, early early days here. As you well know, Novo Nordisk was first to market there. I saw a report this morning that it has something like 90% market share. So, how are you all addressing that? What are you doing to to up those prescriptions for Fundao?
01:44Speaker A
Yeah, it’s early days. We are actually happy to see the progress that we are seeing with Fundeo. You mentioned the number for the quarter, but this is actually the growth that we see actually week over week. It’s important to highlight that it has been roughly 45 days that we have our full commercial open efforts in the US market. What I mean by that is we got actually access on all three PBMs as of June 1st with the last one on CVS
02:16Speaker A
Then we started our consumer campaign in mid-June. So it has been only like again 45 days that we have been very active on the consumer side. And last but not least, again, we added now the bridge program that now Medicare patients could have access both to Fundeo, but also Sebond. So early days, we continue to see great progress on the TRX and the patients that we are saving. just to give you an idea, this is almost double in the last 45 days
02:49Speaker A
And to your point, again, in terms of new prescriptions, very compelling one and every four is actually coming to Fundeo. What is very important is that this is expanding the class. The orals are expanding the class because you mentioned the numbers for Sebond. We continue to see very, very strong growth on the injectables as well. So all along, we assume that the orals will help to reach more patients and that’s what we are seeing
03:22Speaker B
So so just to be clear on this point, Lucas. so it’s not existing patients who are taking the injectables who are converting to the oral medication. It’s new folks who are who are getting the oral medication?
03:38Lucas
80% are new patients to the class. So, this is all along the uh the the expansion that we are seeing. The patients on injectables are happy and well served and we continue to get the feedback from physicians and patients as well. And what we are seeing now is again the early start of the orals and you see again the progress that we are seeing with Fundeo, very very important
